Rallybio ("The Company") is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. The Company’s most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare hematological disease that impacts fetuses and newborns.